Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

New frontiers in chronic lymphocytic leukemia on the way to curing the disease

New frontiers in chronic lymphocytic leukemia on the way to curing the disease editorial memo (2022) 15:3 https://doi.org/10.1007/s12254-022-00795-9 New frontiers in chronic lymphocytic leukemia on the way to curing the disease Philipp Staber Accepted: 7 January 2022 © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2022 References Chronic lymphocytic leukemia (CLL) is the most com- mon leukemia in the western world and is consid- ered to be incurable. In the last 10 years, novel ther- Cited Literature apeutics, like B cell receptor blockers and the bcl-2 1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, inhibitor venetoclax have transformed the prognosis Dighiero G, Döhner H, et al. iwCLL guidelines for diag- for CLL patients [1]. In this issue of the Magazine of nosis, indications for treatment, response assessment, and European Medical Oncology (MEMO),we discuss the supportive management of CLL. Blood. 2018;131:2745–60. perspectives of novel strategies to actually cure CLL 2. Heintel D. BTKi, venetoclax, obinutuzumab: what is the patients. ideal combination?. memo. 2021. https://doi.org/10.1007/ Daniel Heintel reviews the current treatment op- s12254-021-00776-4. 3. Prochazka KT, Uhl B. Bcl2 inhibitor venetoclax +/– Anti- tions for patients with CLL with respect to potential CD20: what do deep remissions mean?. memo. 2021. optimal treatment combinations [2]. Katharina Proc- https://doi.org/10.1007/s12254-021-00778-2. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

New frontiers in chronic lymphocytic leukemia on the way to curing the disease

New frontiers in chronic lymphocytic leukemia on the way to curing the disease

Abstract

editorial memo (2022) 15:3 https://doi.org/10.1007/s12254-022-00795-9 New frontiers in chronic lymphocytic leukemia on the way to curing the disease Philipp Staber Accepted: 7 January 2022 © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2022 References Chronic lymphocytic leukemia (CLL) is the most com- mon leukemia in the western world and is consid- ered to be incurable. In the last 10 years, novel ther- Cited Literature apeutics, like...
Loading next page...
 
/lp/springer-journals/new-frontiers-in-chronic-lymphocytic-leukemia-on-the-way-to-curing-the-UzlXnewCEs
Publisher
Springer Journals
Copyright
2022 The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-022-00795-9
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2022) 15:3 https://doi.org/10.1007/s12254-022-00795-9 New frontiers in chronic lymphocytic leukemia on the way to curing the disease Philipp Staber Accepted: 7 January 2022 © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2022 References Chronic lymphocytic leukemia (CLL) is the most com- mon leukemia in the western world and is consid- ered to be incurable. In the last 10 years, novel ther- Cited Literature apeutics, like B cell receptor blockers and the bcl-2 1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, inhibitor venetoclax have transformed the prognosis Dighiero G, Döhner H, et al. iwCLL guidelines for diag- for CLL patients [1]. In this issue of the Magazine of nosis, indications for treatment, response assessment, and European Medical Oncology (MEMO),we discuss the supportive management of CLL. Blood. 2018;131:2745–60. perspectives of novel strategies to actually cure CLL 2. Heintel D. BTKi, venetoclax, obinutuzumab: what is the patients. ideal combination?. memo. 2021. https://doi.org/10.1007/ Daniel Heintel reviews the current treatment op- s12254-021-00776-4. 3. Prochazka KT, Uhl B. Bcl2 inhibitor venetoclax +/– Anti- tions for patients with CLL with respect to potential CD20: what do deep remissions mean?. memo. 2021. optimal treatment combinations [2]. Katharina Proc- https://doi.org/10.1007/s12254-021-00778-2.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Feb 1, 2022

Keywords: oncology; medicine/public health, general

There are no references for this article.